Disruptive Approaches in Major Depressive Disorder Pipeline: Assessing the Transformative Potential of 75+ Key Companies | AbbVie, Gedeon Richter, Intra-Cellular Therapies, GH Research, and others

Posted on
by

Disruptive Approaches in Major Depressive Disorder Pipeline: Assessing the Transformative Potential of 75+ Key Companies | AbbVie, Gedeon Richter, Intra-Cellular Therapies, GH Research, and others

(Albany, United States) As per DelveInsight’s assessment, globally, the Major Depressive Disorder pipeline constitutes 75+ key companies continuously working towards developing 75+ Major Depressive Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Major Depressive Disorder Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Major Depressive Disorder NDA approvals (if any), and product development activities comprising the technology, Major Depressive Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

To explore more information on the latest breakthroughs in the Major Depressive Disorder pipeline treatment landscape of the report, click here @ Major Depressive Disorder Pipeline Outlook

 

Key Takeaways from the Major Depressive Disorder Pipeline Report

  • DelveInsight’s Major Depressive Disorder Pipeline analysis depicts a robust space with 75+ active players working to develop 75+ pipeline treatment therapies.
  • The leading Major Depressive Disorder Companies in the market include GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others
  • Promising Major Depressive Disorder Pipeline Therapies in the various stages of development include Brexpiprazole, Desvenlafaxine Succinate Sustained-Release 10mg, Cariprazine, Antidepressant Therapy (ADT), TC-5214, ADT, Aripiprazole+ ADT, BTRX-335140, Vortioxetine, Duloxetine, Escitalopram, SEP-363856, and others.
  • On April 2023, BlackThorn Therapeutics Inc announced a study of phase 2 clinical trials for BTRX-335140. A proof of concept (POC) study evaluating the impact of BTRX-335140 (NMRA-335140) relative to placebo on symptoms of major depressive disorder (MDD) in adult participants with MDD and symptoms of anhedonia and anxiety following 8 weeks of double-blind treatment as assessed by the HAMD-17 Scale.
  • On May 2023, Otsuka Pharmaceutical Development & Commercialization Inc announced a study of phase 2 & 3 clinical trials for SEP-363856. This is a Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder (MDD).

 

Major Depressive Disorder Overview

Major Depressive Disorder (MDD), also referred to as clinical depression, is a significant medical condition that can affect many areas of your life. It impacts mood and behavior as well as various physical functions, such as appetite and sleep.

 

To explore more information on the latest breakthroughs in the Major Depressive Disorder Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/major-depressive-disorder-pipeline-insight

 

Major Depressive Disorder Emerging Drugs Profile

  • SAGE-217: Sage Therapeutics
  • REL-1017: Relmada Therapeutics, Inc
  • Seltorexant: Minerva Sciences
  • SP-624: Sirtsei Pharmaceuticals, Inc.
  • SPL026: Small Pharma
  • PDC-1421: BioLite Inc

 

Major Depressive Disorder Pipeline Therapeutics Assessment

There are approx. 75+ key companies which are developing the therapies for Major Depressive Disorder. The Major Depressive Disorder companies which have their Major Depressive Disorder drug candidates in the most advanced stage, i.e. Preregistration include SAGE Therapeutics.

 

Request a sample and discover the recent advances in Major Depressive Disorder Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/major-depressive-disorder-pipeline-insight

 

Major Depressive Disorder Drugs and Companies

  • Brexpiprazole: Otsuka Pharmaceuticals
  • Cariprazine: Gedeon Richter Ltd
  • TC-5214: AstraZeneca
  • BTRX-335140: BlackThorn Therapeutics Inc

 

Major Depressive Disorder Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Some of the Companies in the Major Depressive Disorder Therapeutics Market include-

GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.

 

Dive deep into rich insights for drugs for Major Depressive Disorder Pipeline, click here for Major Depressive Disorder Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/major-depressive-disorder-pipeline-insight

 

Scope of the Major Depressive Disorder Pipeline Report

  • Coverage- Global
  • Major Depressive Disorder Companies- GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.
  • Major Depressive Disorder Pipeline Therapies- Brexpiprazole, Desvenlafaxine Succinate Sustained-Release 10mg, Cariprazine, Antidepressant Therapy (ADT), TC-5214, ADT, Aripiprazole+ ADT, BTRX-335140, Vortioxetine, Duloxetine, Escitalopram, SEP-363856, and others
  • Major Depressive Disorder Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Major Depressive Disorder Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/major-depressive-disorder-pipeline-insight

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Major Depressive Disorder: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Major Depressive Disorder – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. SAGE-217: Sage Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SP-624: Sirtsei Pharmaceuticals, Inc.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. SPL026: Small Pharma
  15. Drug profiles in the detailed report…..
  16. Preclinical Stage Products
  17. Drug Name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Major Depressive Disorder Key Companies
  21. Major Depressive Disorder Key Products
  22. Major Depressive Disorder- Unmet Needs
  23. Major Depressive Disorder- Market Drivers and Barriers
  24. Major Depressive Disorder- Future Perspectives and Conclusion
  25. Major Depressive Disorder Analyst Views
  26. Major Depressive Disorder Key Companies
  27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services